Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases

Autor: Thibaud Damy, Guillaume Bourel, Michel Slama, Vincent Algalarrondo, Olivier Lairez, Pauline Fournier, Jérôme Costa, Françoise Pelcot, Agnès Farrugia, Isabelle Durand Zaleski, Hervé Lilliu, Caroline Rault, Mathilde Bartoli, Stéphane Fievez, Anna Granghaud, Jeremie Rudant, Agathe Coste, Charlotte Noirot Cosson, Pierre-Alexandre Squara, Marion Narbeburu, Bertrand De Neuville, Philippe Charron

Publikováno v: Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-9 (2023)

Abstract Background Precise data about ATTR-CM incidence rates at national level are scarce. Consequently, this study aimed to estimate the annual incidence and survival of transthyretin amyloid cardiomyopathy (ATTR-CM) in France between 2011 and 201

Externí odkaz: https://doaj.org/article/6947c5f5497e43788cf4bba80c998e29

Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France

Autor: Fanny Porte, Anna Granghaud, Jane Chang, Mairead Kearney, Aya Morel, Ingrid Plessala, Hélène Cawston, Julie Roiz, Ying Xiao, Marie-Noelle Solbes, Prisca Lambert, Alain Ravaud, Yohann Loriot, Antoine Thiery-Vuillemin, Pierre Lévy

Publikováno v: PLoS ONE, Vol 19, Iss 5 (2024)

Externí odkaz: https://doaj.org/article/c4c77806b3f547ec86eb58872383f9bf

Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.

Autor: Henri Leleu, Jean Benoit Arlet, Anoosha Habibi, Maryse Etienne-Julan, Mehdi Khellaf, Yolande Adjibi, France Pirenne, Marine Pitel, Anna Granghaud, Cynthia Sinniah, Mariane De Montalembert, Frédéric Galacteros

Publikováno v: PLoS ONE, Vol 16, Iss 7, p e0253986 (2021)

ContextSickle cell disease (SCD) is a severe hematological disorder. The most common acute complication of SCD is vaso-occlusive crisis (VOC), but SCD is a systemic disease potentially involving all organs. SCD prevalence estimates rely mostly on ext

Externí odkaz: https://doaj.org/article/d93217752aa84b43834f79de4d1676b4

Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data

Autor: Omer Zaidi, Rongzhe Liu, Jingyan Yang, Anna Granghaud, Jennifer Stephens

Publikováno v: Journal of Medical Economics. 24:665-674

NYVEPRIA, a pegfilgrastim (a long-acting granulocyte colony-stimulating factor [G-CSF]) biosimilar, was recently recommended for marketing authorization in Europe for decreasing the incidence of febrile neutropenia (FN) in patients with non-myeloid m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c83bc29ec8f1856ede340932a70e90
https://doi.org/10.1080/13696998.2021.1922252

Epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) in France, a study based on the systeme national des donnees de sante (SNDS) the French nationwide claims database

Autor: M. Slama, S. Fievez, Thibaud Damy, V. Algalarrondo, I. Durand-Zaleski, A. Granghaud, C. Rault, Philippe Charron, G. Bourel, B. De Neuville, F. Pelcot, M. Bartoli, J. Rudant, Olivier Lairez, H. Lilliu

Publikováno v: European Heart Journal
European Heart Journal, Oxford University Press (OUP), 2021, 42 (supplément 1), pp.3131
European Journal of Heart Failure
European Journal of Heart Failure, European Society of Cardiology (Wiley), 2021, 23 (2, SI), pp.305

Transthyretin (TTR) Amyloid Cardiomyopathy (ATTR-CM) is a rare, progressively debilitating, fatal disease with poor prognosis caused by amyloid deposition of fibrils derived from the serum protein TTR in the extracellular matrix of the heart. As amyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ee27fb117917c7c924c627d9b6eb01
https://hal-u-picardie.archives-ouvertes.fr/hal-03584065